CR20220374A - Métodos de tratamiento de la esplenomegalia - Google Patents

Métodos de tratamiento de la esplenomegalia

Info

Publication number
CR20220374A
CR20220374A CR20220374A CR20220374A CR20220374A CR 20220374 A CR20220374 A CR 20220374A CR 20220374 A CR20220374 A CR 20220374A CR 20220374 A CR20220374 A CR 20220374A CR 20220374 A CR20220374 A CR 20220374A
Authority
CR
Costa Rica
Prior art keywords
methods
splenomegaly
treating
treating splenomegaly
therapeutic methods
Prior art date
Application number
CR20220374A
Other languages
English (en)
Inventor
Wayne Philip Rothbaum
Original Assignee
Telios Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telios Pharma Inc filed Critical Telios Pharma Inc
Publication of CR20220374A publication Critical patent/CR20220374A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describen métodos terapéuticos y composiciones farmacéuticas para tratar la esplenomegalia en un sujeto humano. En ciertas realizaciones, la invención incluye métodos terapéuticos para tratar la esplenomegalia usando un inhibidor de BTK.
CR20220374A 2020-01-08 2021-01-08 Métodos de tratamiento de la esplenomegalia CR20220374A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08
PCT/US2021/012696 WO2021142257A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Publications (1)

Publication Number Publication Date
CR20220374A true CR20220374A (es) 2023-01-25

Family

ID=76788747

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220374A CR20220374A (es) 2020-01-08 2021-01-08 Métodos de tratamiento de la esplenomegalia

Country Status (15)

Country Link
EP (2) EP3980069A4 (es)
JP (2) JP7771064B2 (es)
KR (1) KR20220130151A (es)
CN (1) CN114423457A (es)
AU (1) AU2021205484A1 (es)
BR (1) BR112022013646A2 (es)
CA (1) CA3164063A1 (es)
CO (1) CO2022010592A2 (es)
CR (1) CR20220374A (es)
IL (1) IL294582A (es)
JO (1) JOP20220168A1 (es)
MA (3) MA57226B1 (es)
MX (1) MX2022008490A (es)
TN (1) TN2022000185A1 (es)
WO (1) WO2021142257A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022008490A (es) * 2020-01-08 2022-10-13 Telios Pharma Inc Metodos de tratamiento de la esplenomegalia.
US20240024314A1 (en) 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
CN118251237A (zh) * 2021-06-16 2024-06-25 泰利奥斯制药公司 与骨髓增殖性肿瘤相关的症状的治疗
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
CN119677518A (zh) * 2022-08-25 2025-03-21 百济神州(苏州)生物科技有限公司 包含(s)-7-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺和草酸的固体形式、其组合物及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
AU2014354769A1 (en) 2013-11-26 2016-05-26 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
RS62713B1 (sr) * 2014-08-11 2022-01-31 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora
US9708348B2 (en) * 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
EP3810590A1 (en) * 2018-06-19 2021-04-28 Merck Patent GmbH Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
CN109942835A (zh) * 2019-03-27 2019-06-28 广州楹鼎生物科技有限公司 一种催化分解木质纤维原料的方法
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
MX2022008490A (es) * 2020-01-08 2022-10-13 Telios Pharma Inc Metodos de tratamiento de la esplenomegalia.

Also Published As

Publication number Publication date
AU2021205484A1 (en) 2022-08-18
JOP20220168A1 (ar) 2023-01-30
CO2022010592A2 (es) 2022-10-31
MA63848B1 (fr) 2024-10-31
CA3164063A1 (en) 2021-07-15
TN2022000185A1 (en) 2024-04-01
EP3980069A1 (en) 2022-04-13
IL294582A (en) 2022-09-01
CN114423457A (zh) 2022-04-29
BR112022013646A2 (pt) 2022-10-04
MA57226B1 (fr) 2023-06-28
MA57226A1 (fr) 2023-02-28
JP2023509968A (ja) 2023-03-10
MA69153A1 (fr) 2025-07-31
JP7771064B2 (ja) 2025-11-17
JP2026027353A (ja) 2026-02-18
WO2021142257A1 (en) 2021-07-15
MX2022008490A (es) 2022-10-13
MA63848A1 (fr) 2024-04-30
KR20220130151A (ko) 2022-09-26
EP4000624A1 (en) 2022-05-25
EP3980069A4 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
CO2022010592A2 (es) Métodos de tratamiento de la esplenomegalia
SA522432691B1 (ar) المركبات الحلقية الماكروية وطرق العلاج المرتبطة بها
MX2022004983A (es) Composiciones de profarmaco y metodos de tratamiento.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
CL2020002833A1 (es) Métodos para tratar cáncer
CY1125104T1 (el) Συνθεσεις φλαγελλινης entrecoccus για χρηση στη θεραπεια
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1124123T1 (el) Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου
MX2025003515A (es) Moduladores de akt1
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
BR112022011228A2 (pt) Formulação farmacêutica líquida, artigo de fabricação, kit e método para tratar uma doença ou distúrbio em um indivíduo
MX393452B (es) Tratamiento de los trastornos depresivos.
MX2025008092A (es) Inhibidores de kif18a y usos de los mismos
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
CO2022000214A2 (es) Composiciones para el tratamiento de la pérdida del cabello
CO2023008676A2 (es) Compuestos polipéptidos modificados con lactama
MX2025008834A (es) Proteinas de fusion anti-pd-1/il-2, composiciones farmaceuticas y aplicaciones terapeuticas
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
CR20220071A (es) Composiciones farmacéuticas y métodos para tratar o prevenir la atrofia muscular espinal
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.
MX2025007132A (es) Metodos para tratar la enfermedad de farber
MX2021004396A (es) Metodos y composiciones para el tratamiento de la mucositis oral.